Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Veracyte (VCYT) Cost of Revenue: 2011-2024

Historic Cost of Revenue for Veracyte (VCYT) over the last 14 years, with Dec 2024 value amounting to $95.4 million.

  • Veracyte's Cost of Revenue rose 8.15% to $24.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $99.0 million, marking a year-over-year increase of 3.32%. This contributed to the annual value of $95.4 million for FY2024, which is 5.97% down from last year.
  • According to the latest figures from FY2024, Veracyte's Cost of Revenue is $95.4 million, which was down 5.97% from $101.5 million recorded in FY2023.
  • Veracyte's Cost of Revenue's 5-year high stood at $101.5 million during FY2023, with a 5-year trough of $52.4 million in FY2020.
  • Its 3-year average for Cost of Revenue is $98.2 million, with a median of $97.6 million in 2022.
  • Its Cost of Revenue has fluctuated over the past 5 years, first spiked by 52.40% in 2021, then fell by 5.97% in 2024.
  • Over the past 5 years, Veracyte's Cost of Revenue (Yearly) stood at $52.4 million in 2020, then surged by 52.40% to $79.8 million in 2021, then increased by 22.19% to $97.6 million in 2022, then climbed by 4.03% to $101.5 million in 2023, then fell by 5.97% to $95.4 million in 2024.